AGIO - Agios Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
43.46
+0.47 (+1.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close42.99
Open43.41
Bid0.00 x 800
Ask0.00 x 800
Day's Range42.95 - 43.75
52 Week Range38.62 - 85.00
Volume247,711
Avg. Volume543,153
Market Cap2.553B
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Agios Rides High on Tibsovo Sales Amid Acute Competition
    Zacks

    Agios Rides High on Tibsovo Sales Amid Acute Competition

    Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.

  • An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 50% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 50% Undervalued

    How far off is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from its intrinsic value? Using the most recent financial...

  • Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript

    AGIO earnings call for the period ending June 30, 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of AGIO earnings conference call or presentation 1-Aug-19 12:00pm GMT

    Q2 2019 Agios Pharmaceuticals Inc Earnings Call

  • Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales
    Zacks

    Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales

    Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.

  • Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

    Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -8.09% and 6.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

    Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Markit

    See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

    Agios Pharmaceuticals Inc NASDAQ/NGS:AGIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding AGIO is favorable, with net inflows of $5.05 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Agios (AGIO) Catches Eye: Stock Jumps 5.4%
    Zacks

    Agios (AGIO) Catches Eye: Stock Jumps 5.4%

    Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%?
    Simply Wall St.

    Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%?

    Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

  • Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]

  • Life sciences VC firm Third Rock raises $770M in its largest round ever
    American City Business Journals

    Life sciences VC firm Third Rock raises $770M in its largest round ever

    One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.

  • Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?
    Zacks

    Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?

    Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
    Zacks

    Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

    Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...

  • Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight
    Insider Monkey

    Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight

    Although it is rapidly approaching 13F season and traders are closely watching oil stocks due to the rising Middle East tensions, several stocks such as Alibaba Group Holding Limited (NYSE:BABA), Altaba Inc. (NASDAQ:AABA), Cisco Systems, Inc. (NASDAQ:CSCO), Agios Pharmaceuticals Inc (NASDAQ:AGIO), and Virtusa Corporation (NASDAQ:VRTU) are in the spotlight for various reasons. Let's analyze why traders are watching each stock […]

  • CNBC

    Stocks making the biggest moves after hours: Agios, Farfetch, Cisco and more

    Shares of Cisco Systems CSCO rose more than 2.5% in extended trading Wednesday after the networking hardware company reported better-than-expected fourth quarter results. The company also gave strong guidance for the fourth quarter with estimated earnings per share and revenue both coming in higher than Refinitiv consensus estimates. Farfetch reported a loss of 22 cents per share, worse than the expected loss of 16 cents per share, and revenue of $174.1 million, higher than the expected $171.1 million, according to Refinitiv consensus estimates.

  • Thomson Reuters StreetEvents

    Edited Transcript of AGIO earnings conference call or presentation 2-May-19 12:00pm GMT

    Q1 2019 Agios Pharmaceuticals Inc Earnings Call